Pharmatech, Inc. Selects OmniComm Systems, Inc. As Its Preferred Electronic Data Capture (EDC) Vendor And Enters Into A Strategic Partnership To Co-Develop Next Generation Solutions For Improving Patient Accrual

CRO and EDC companies team up to co-develop a Patient Repository Solution for improving patient accrual for their physicians conducting clinical trial research

FT. LAUDERDALE, FL - July 2, 2007 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that it will partner with Pharmatech, Inc., a Research Management Organization (RMO), to build a patient registry database that will improve patient accrual in clinical trials. The database will leverage the data mining functionality inherent in OmniComm's First in Functionality™ TrialMaster® EDC solution to facilitate the screening and identification of patient candidates for cutting-edge oncology research. OmniComm will be the exclusive choice for Pharmatech and their network physicians who utilize EDC for clinical trials. Pharmatech will begin using TrialMaster in a multi-center, Phase II clinical trial for advanced Non-Small Cell Lung Cancer (NSCLC).

"OmniComm is pleased that Pharmatech chose our EDC solution, TrialMaster, for their clients that want to benefit from the use of EDC. And more importantly, we share a united vision with Pharmatech to bring new, integrated solutions for data mining and patient accrual to the clinical development marketplace. This new Patient Repository solution will create a pre-populated database of patient information that is linked to our EDC solution and can be used by researchers to find patients quickly and easily for their trials," commented Cornelis F. Wit, CEO of OmniComm Systems. Mr. Wit added, "This will be the first of its kind solution between a CRO and an EDC company that focuses on the problem of patient accrual. Pharmatech's unique status as a CRO/SMO and tight affiliation with their network of physicians with access to patient information, makes them the perfect partner to tackle this initiative."

Matthew Wiener, CEO of Pharmatech, states that, "The collaboration with OmniComm allows Pharmatech to blend our expertise in the community-based oncology setting with OmniComm's strength in the hospital and academic settings to provide real power to oncology clinical trials. The OmniComm e-clinical trial platform will boost the development of our progressive clinical trials business model by further building upon our innovative patient enrollment and data management programs."

About Pharmatech
Pharmatech, Inc., (www.pharmatech.com) headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research, while protecting patient safety. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials.

Pharmatech focuses on access to patients and clinical investigators through organized research networks. The oncology network consists of over 1200 community-based cancer researchers that provide innovative treatment options to cancer patients through clinical trial opportunities. The Network model provides a foundation for the development and utilization of therapeutic products among sponsors, investigators and patients.

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled "The Promise of Next-Gen eClinical Trial Software," by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Back